Impel Pharmaceuticals Inc. (IMPL)
Price:
0.04 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
NEWS
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
prnewswire.com
2023-12-19 23:10:00Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE , Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets. To facilitate an orderly sale process, the Company has filed voluntary petitions to commence chapter 11 proceedings in the U.S. Bankruptcy Court for the Northern District of Texas (the "Court"), which will provide interested parties the opportunity to submit higher and better offers.
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
investorplace.com
2023-09-08 08:14:53Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
investorplace.com
2023-08-16 08:50:03Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
globenewswire.com
2023-06-15 08:00:00Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
globenewswire.com
2023-05-05 08:00:00SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
seekingalpha.com
2023-03-24 15:20:02Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2023-03-24 11:27:19Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
globenewswire.com
2023-03-17 08:00:00SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
globenewswire.com
2023-03-03 16:01:00SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-14 13:24:05Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-08-15 10:33:07Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-15 10:32:12Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 3.54% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
seekingalpha.com
2022-06-28 02:00:23Impel Pharmaceuticals has slipped under the radar since its IPO back in April of last year. The company has made significant progress with its launch of Trudhesa. Impel continues to see Trudhesa prescription momentum increasing and is confident that it will see growth in both new and refill prescriptions.
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
globenewswire.com
2022-06-09 08:00:00Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
globenewswire.com
2022-06-08 08:00:00SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-17 16:52:04Impel NeuroPharma, Inc. (NASDAQ:IMPL ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman of the Board & Chief Executive Officer Len Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen, and Welcome to Impel Pharmaceuticals' First Quarter 2022 Earnings Corporate Update Conference Call. At this time, all participants are in listen-only mode.
No data to display
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
prnewswire.com
2023-12-19 23:10:00Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE , Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets. To facilitate an orderly sale process, the Company has filed voluntary petitions to commence chapter 11 proceedings in the U.S. Bankruptcy Court for the Northern District of Texas (the "Court"), which will provide interested parties the opportunity to submit higher and better offers.
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
investorplace.com
2023-09-08 08:14:53Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
investorplace.com
2023-08-16 08:50:03Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
globenewswire.com
2023-06-15 08:00:00Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
globenewswire.com
2023-05-05 08:00:00SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
seekingalpha.com
2023-03-24 15:20:02Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2023-03-24 11:27:19Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
globenewswire.com
2023-03-17 08:00:00SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
globenewswire.com
2023-03-03 16:01:00SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-14 13:24:05Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-08-15 10:33:07Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-15 10:32:12Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 3.54% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
seekingalpha.com
2022-06-28 02:00:23Impel Pharmaceuticals has slipped under the radar since its IPO back in April of last year. The company has made significant progress with its launch of Trudhesa. Impel continues to see Trudhesa prescription momentum increasing and is confident that it will see growth in both new and refill prescriptions.
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
globenewswire.com
2022-06-09 08:00:00Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
globenewswire.com
2022-06-08 08:00:00SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-17 16:52:04Impel NeuroPharma, Inc. (NASDAQ:IMPL ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman of the Board & Chief Executive Officer Len Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen, and Welcome to Impel Pharmaceuticals' First Quarter 2022 Earnings Corporate Update Conference Call. At this time, all participants are in listen-only mode.